Qualigen Therapeutics Announces First Patient Dosed In The Phase 1a Clinical Trial Of QN-302 For Treatment Of Advanced Or Metastatic Solid Tumors
Qualigen Therapeutics Announces First Patient Dosed In The Phase 1a Clinical Trial Of QN-302 For Treatment Of Advanced Or Metastatic Solid Tumors
Qualigen Therapeutics 宣布在用于治疗晚期或转移性实体瘤的 QN-302 的 1a 期临床试验中首位患者给药
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. The first clinical site is located at START Midwest in Grand Rapids, Michigan.
Qualigen Therapeutics, Inc.（纳斯达克股票代码：QLGN）是一家临床阶段的治疗公司，专注于开发有可能被指定为孤儿药的成人和儿科癌症的治疗方法。该公司今天宣布，1a期临床试验的首位患者已经服用了 QN-302，这是一种潜在的同类首创、正在研究的G-四联体（G4）选择性转录抑制剂，专为治疗晚期或转移性实体瘤而设计。第一个临床中心位于密歇根州大瀑布城的START Midwest。
QN-302 works by selectively stabilizing G4 complexes prevalent in the promoter region of oncogenes in many tumor types, impeding transcription of G4-containing cancer genes, and may...
QN-302 的工作原理是选择性地稳定许多肿瘤类型...
登录免费看全文
登录/注册